Protalix BioTherapeutics (PLX) Operating Expenses (2010 - 2026)

Protalix BioTherapeutics' Operating Expenses history runs 17 years deep, the most recent figure standing at $1.3 million for Q1 2026.

• On a quarterly basis, Operating Expenses fell 79.15% year-over-year to $1.3 million in Q1 2026; TTM through Mar 2026 was $16.4 million, a 28.44% decrease from a year earlier, with the FY2025 full-year figure at $21.0 million, up 18.38% from the prior year.
• Operating Expenses declined to $1.3 million in Q1 2026 per PLX's latest filing, from $2.6 million in the prior quarter.
• Across five years, Operating Expenses topped out at $11.9 million in Q1 2022 and bottomed at $1.3 million in Q1 2026.
• The 5-year median for Operating Expenses is $7.4 million (2024), against an average of $7.0 million.
• Across the five-year window, Operating Expenses jumped 38.57% in 2025 and tumbled 79.15% in 2026, its largest moves.
• Year by year, Operating Expenses stood at $8.7 million in 2022, then fell by 16.87% to $7.2 million in 2023, then slumped by 73.8% to $1.9 million in 2024, then surged by 38.57% to $2.6 million in 2025, then plunged by 52.28% to $1.3 million in 2026.
• Per Business Quant, the three latest PLX Operating Expenses figures stand at $1.3 million (Q1 2026), $2.6 million (Q4 2025), and $7.8 million (Q3 2025).